IL17A and inflammatory response: By acting on (1) IL-23R expression which increases the cellular sensitivity to IL-23, (2) on CCL20, a chemokine which directs the movement of CCR6+ IL-17 producers, and (3) IL-17 production, a strong positive feedback loop supporting “type 17 inflammation” is created which plays an important role in chronic psoriatic inflammation.